Frontotemporal Disorder Treatment Market
Global Frontotemporal Disorder Treatment Market Size, Share & Trends Analysis Report by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulant, Other) by Disease Type (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorder) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) Forecast Period (2020-2026)
The global frontotemporal disorder treatment market is projected to grow at a considerable CAGR of around 5% during the forecast period (2020-2026). The increasing prevalence of frontotemporal disorder along with the growing geriatric population which is more susceptible to this kind of disorder is expected to be key factors promoting the growth of the global frontotemporal disorder treatment market. According to the World Health Organization (WHO), in 2019 around 50 million people are living with dementia and the number is anticipated to get three times by 2050. Moreover, nearly 10 million new cases are anticipated to increase every year. Frontotemporal disorders are forms of dementia caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD).
With the growing number of patients suffering from the frontotemporal disorder, several private or non-profit organizations are actively focusing on drug development procedures. For instance, in 2019, the National Institute of Health (NIH) had spent nearly $387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). Therefore, the rising funding initiatives by a non-profit organization such as the Bluefield Project Organization, CurePSP, Inc. Alzheimer Discovery Foundation (ADDF), Tau Consortium Organization, Association for Frontotemporal Degeneration (AFTD) to support drug research initiatives is anticipated to drive the growth of the frontotemporal disorder treatment industry across the globe. However, stringent government regulations, lack of awareness, and lack of novel therapies are the key factors anticipated to hinder the growth of the global market.
Segmental Outlook
The frontotemporal disorder treatment market is segmented on the basis of drug class, disease type, and distribution channel. Based on the drug class, the market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. Antidepressants are expected to witness considerable growth based on drug class. Based on disease type, the market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorder. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others.
Antidepressants to be considerable segment based on Treatment
The increasing use of anti-depressants to overcome different brain-related disorders such as neuropathic pain, anxiety disorders, dysthymia, obsessive-compulsive disorder (OCD), chronic pain, and so on is a key factor contributing towards the growth of this market segment. Furthermore, the rising number of new drug launches is anticipated to drive the growth of this market segment. For instance, in October 2018, Lundbeck A/s had launched Brintellix tablets in India. The tablets are antidepressants for the treatment of Major Depressive Disorder (MDD).
Global Frontotemporal Disorder Treatment Market Share by Drug Class, 2019 (%)
Regional Outlook
The global frontotemporal disorder treatment market is further segmented on the basis of geography including North America, Europe, Asia-Pacific and Rest of the World. North America is anticipated to hold a considerable market share during the forecast period. High prevalence of frontotemporal disorder treatment along with the presence of huge funding for R&D of the treatment therapies are anticipated to be the key factors contributing towards the high share of the North American region. According to the Alzheimer’s Association, in 2019, 5.8 million Americans were living with Alzheimer’s Dementia. The availability of funding for the R&D of neurological disorders by major organizations such as The National Institute of Neurological Disorders and Stroke and National Institute of Health is anticipated to make a huge contribution towards the high share of the market in the region.
Global Frontotemporal Disorder Treatment Market Growth, by Region 2020-2026
Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026
Improving healthcare infrastructure, growing R&D funding, increasing per capita healthcare expenditure, along with the presence of patients suffering from the frontotemporal disorders are anticipated to be the key factors driving the growth of the frontotemporal disorder treatment market in the Asia-Pacific region. Furthermore, the growing geriatric population in the major economies of the region such as China, India, Japan, and South Korea is another factor contributing towards the robust growth of the frontotemporal disorder treatment market in the Asia-Pacific region. However, lack of proper healthcare infrastructure along with low awareness related to the treatment options among the people of the low-income economies of the region is anticipated to hinder the growth of the frontotemporal disorder treatment market in the Asia-Pacific region.
Market Players Outlook
The key players of frontotemporal disorder treatment market include Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals Industries, Ltd., Eli Lily and Company, GlaxoSmithKline Plc., Novartis AG, Merck & Company, Inc., Allergen plc, F. Hoffmann-La Roche Ltd., and so on. The major players of the frontotemporal disorder treatment market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global frontotemporal disorder treatment market.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global frontotemporal disorder treatment market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Frontotemporal Disorders Treatment Market by Drug Class
5.1.1. Cognitive Enhancers
5.1.2. Antipsychotics
5.1.3. Antidepressants
5.1.4. CNS Stimulant
5.1.5. Other
5.2. Global Frontotemporal Disorders Treatment Market by Disease Indication
5.2.1. Frontotemporal Dementia
5.2.2. Primary Progressive Aphasia
5.2.3. Movement Disorder
5.3. Global Frontotemporal Disorders Treatment Market by Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies
5.3.3. Others
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Allergan PLC
7.2. Apotex Inc.
7.3. AstraZeneca PLC
7.4. Bausch Health Companies, Inc.
7.5. Eli Lily and Co.
7.6. F. Hoffmann-La Roche Ltd.
7.7. GlaxoSmithKline PlPLC
7.8. Intas Pharmaceutical Ltd.
7.9. Johnson & Johnson Service, Inc.
7.10. Merck & Company, Inc.
7.11. Mylan N.V.
7.12. Novartis AG
7.13. Pfizer, Inc.
7.14. Sanofi S.A.
7.15. Teva Pharmaceuticals Industries, Ltd.
1. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. GLOBAL COGNITIVE ENHANCERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL ANTIPSYCHOTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL CNS STIMULANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
8. GLOBAL FRONTOTEMPORAL DEMENTIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL PRIMARY PROGRESSIVE APHASIA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
10. GLOBAL MOVEMENT DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
12. GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
13. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
14. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
15. NORTH AMERICA FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
16. NORTH AMERICAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
17. NORTH AMERICAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
18. NORTH AMERICAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
19. EUROPE FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
20. EUROPE FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
21. EUROPE FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
22. EUROPE FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
23. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
24. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
25. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
26. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
27. REST OF THE WORLD FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
28. REST OF THE WORLD FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE INDICATION, 2019-2026 ($ MILLION)
29. REST OF THE WORLD FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
1. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
2. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE BY DISEASE INDICATION, 2019 VS 2026 (%)
3. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE BY DISTRIBUTION CHANNEL, 2019 VS 2026 (%)
4. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
5. THE US FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. UK FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. FRANCE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
9. GERMANY FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. ITALY FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. SPAIN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. ROE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
17. REST OF THE WORLD FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
